Recurrence morbidity of olfactory neuroblastoma.
esthesioneuroblastoma
olfactory neuroblastoma
recurrence
sinonasal malignancy
skull base
Journal
International forum of allergy & rhinology
ISSN: 2042-6984
Titre abrégé: Int Forum Allergy Rhinol
Pays: United States
ID NLM: 101550261
Informations de publication
Date de publication:
03 Apr 2024
03 Apr 2024
Historique:
revised:
20
03
2024
received:
20
02
2024
accepted:
22
03
2024
medline:
3
4
2024
pubmed:
3
4
2024
entrez:
3
4
2024
Statut:
aheadofprint
Résumé
With modern treatment paradigms, olfactory neuroblastoma (ONB) has favorable overall survival (OS); however, the incidence of recurrence remains high. The primary aims of this study were to delineate the prognosis of recurrence of ONB and explore how recurrence subsites are associated with OS, disease-specific survival (DSS), and further recurrence. A retrospective chart review of ONB cases from nine academic centers between 2005 and 2021 was completed. Tumor characteristics, recurrence subsites, timelines to recurrence, additional recurrences, and survival estimates were determined using descriptive and time-to-event analyses. A final cohort of 233 patients was identified, with 70 (30.0%) patients recurring within 50.4 (standard deviation ±40.9) months of diagnosis on average, consisting of local (50%), neck (36%), intracranial (9%), and distant (6%) recurrence. Compared with subjects without recurrence, patients with recurrence had significantly different primary American Joint Committee on Cancer T stage (p < 0.001), overall stage (p < 0.001), and modified Kadish scores (p < 0.001). Histopathology identified that dural involvement and positive margins were significantly greater in recurrent cases. First recurrence was significantly associated with worse 5-year DSS (hazard ratio = 5.62; p = 0.003), and subjects with neck or local recurrence had a significantly better DSS compared to intracranial or distant recurrence. Recurrent cases of ONB have significantly different stages and preoperative imaging factors. Patients with local or neck recurrence, however, have better DSS than those with intracranial or distant recurrence, independent of initial tumor stage or Hyams grade. Identifying specific factors that confer an increased risk of recurrence and DSS is important for patient counseling in addition to surveillance planning.
Sections du résumé
BACKGROUND
BACKGROUND
With modern treatment paradigms, olfactory neuroblastoma (ONB) has favorable overall survival (OS); however, the incidence of recurrence remains high. The primary aims of this study were to delineate the prognosis of recurrence of ONB and explore how recurrence subsites are associated with OS, disease-specific survival (DSS), and further recurrence.
METHODS
METHODS
A retrospective chart review of ONB cases from nine academic centers between 2005 and 2021 was completed. Tumor characteristics, recurrence subsites, timelines to recurrence, additional recurrences, and survival estimates were determined using descriptive and time-to-event analyses.
RESULTS
RESULTS
A final cohort of 233 patients was identified, with 70 (30.0%) patients recurring within 50.4 (standard deviation ±40.9) months of diagnosis on average, consisting of local (50%), neck (36%), intracranial (9%), and distant (6%) recurrence. Compared with subjects without recurrence, patients with recurrence had significantly different primary American Joint Committee on Cancer T stage (p < 0.001), overall stage (p < 0.001), and modified Kadish scores (p < 0.001). Histopathology identified that dural involvement and positive margins were significantly greater in recurrent cases. First recurrence was significantly associated with worse 5-year DSS (hazard ratio = 5.62; p = 0.003), and subjects with neck or local recurrence had a significantly better DSS compared to intracranial or distant recurrence.
CONCLUSIONS
CONCLUSIONS
Recurrent cases of ONB have significantly different stages and preoperative imaging factors. Patients with local or neck recurrence, however, have better DSS than those with intracranial or distant recurrence, independent of initial tumor stage or Hyams grade. Identifying specific factors that confer an increased risk of recurrence and DSS is important for patient counseling in addition to surveillance planning.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 ARS‐AAOA, LLC.
Références
Faragalla H, Weinreb I. Olfactory neuroblastoma: a review and update. Adv Anat Pathol. 2009;16(5):322‐331.
Thompson LD. Olfactory neuroblastoma. Head Neck Pathol. 2009;3(3):252‐259.
Sjöstedt S, Jensen DH, Jakobsen KK, et al. Incidence and survival in sinonasal carcinoma: a Danish population‐based, nationwide study from 1980 to 2014. Acta Oncol. 2018;57(9):1152‐1158.
Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res. 1997;17(4A):2683‐2706.
Wang EW, Zanation AM, Gardner PA, et al. ICAR: endoscopic skull‐base surgery. Int Forum Allergy Rhinol. 2019;9(S3):S145‐S365.
Choby G, Geltzeiler M, Almeida JP, et al. Multicenter survival analysis and application of an olfactory neuroblastoma staging modification incorporating Hyams grade. JAMA Otolaryngol Head Neck Surg. 2023;149(9):837‐844.
Geltzeiler M, Choby GW, Ji KSY, et al. Radiographic predictors of occult intracranial involvement in olfactory neuroblastoma patients. Int Forum Allergy Rhinol. 2023;13(10):1876‐1888.
Devaiah AK, Andreoli MT. Treatment of esthesioneuroblastoma: a 16‐year meta‐analysis of 361 patients. Laryngoscope. 2009;119(7):1412‐1416.
Fu TS, Monteiro E, Muhanna N, Goldstein DP, de Almeida JR. Comparison of outcomes for open versus endoscopic approaches for olfactory neuroblastoma: a systematic review and individual participant data meta‐analysis. Head Neck. 2016;38(suppl 1):E2306‐E2316.
Su SY, Bell D, Ferrarotto R, et al. Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck. 2017;39(8):1671‐1679.
Miller KC, Marinelli JP, Janus JR, et al. Induction therapy prior to surgical resection for patients presenting with locally advanced esthesioneuroblastoma. J Neurol Surg B Skull Base. 2021;82(suppl 3):e131‐e137.
Platek ME, Merzianu M, Mashtare TL, et al. Improved survival following surgery and radiation therapy for olfactory neuroblastoma: analysis of the SEER database. Radiat Oncol. 2011;25(6):41.
Van Gompel JJ, Giannini C, Olsen KD, et al. Long‐term outcome of esthesioneuroblastoma: Hyams grade predicts patient survival. J Neurol Surg B Skull Base. 2012;73(5):331‐336.
McMillan RA, Van Gompel JJ, Link MJ, et al. Long‐term oncologic outcomes in esthesioneuroblastoma: an institutional experience of 143 patients. Int Forum Allergy Rhinol. 2022;12(12):1457‐1467.
Amin MB, Edge SB, Greene FL, eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.
Hyams VJ. Olfactory neuroblastoma (case 6). In: Batsakis JG, Hyams VJ, Morales AR, eds. Special Tumors of the Head and Neck. Chicago: ASCP Press; 1982:24‐29.
Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery. 1993;32(05):706‐714.
Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970‒1990. Laryngoscope. 1992;102(08):843‐849.
Rothman KJ, Greenland S. Cohort studies. In: Rothman KJ, Greenland S, eds. Modern Epidemiology. 2nd ed. Lippincott‐Raven; 1998:79‐91.
Ni G, Pinheiro‐Neto CD, Iyoha E, et al. Recurrent esthesioneuroblastoma: long‐term outcomes of salvage therapy. Cancers. 2023;15(5):1506.
Abdelmeguid AS, Bell D, Roberts D, et al. Long‐term outcomes of olfactory neuroblastoma: MD Anderson Cancer Center experience and review of the literature. Laryngoscope. 2022;132(2):290‐297.
Spielman DB, Liebowitz A, Grewal M, et al. Exclusively endoscopic surgical resection of esthesioneuroblastoma: a systematic review. World J Otorhinolaryngol Head Neck Surg. 2022;8(1):66‐72.
Kuan EC, Wang EW, Adappa ND, et al. International consensus statement on allergy and rhinology: sinonasal tumors. Int Forum Allergy Rhinol. 2024;14(2):149‐608.
Naples JG, Spiro J, Tessema B, Kuwada C, Kuo CL, Brown SM. Neck recurrence and mortality in esthesioneuroblastoma: implications for management of the N0 neck. Laryngoscope. 2016;126(6):1373‐1379.
Lechner M, Takahashi Y, Turri‐Zanoni M, et al. Clinical outcomes, Kadish‐INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. Eur J Cancer. 2022;162:221‐236.
Bell D, Saade R, Roberts D, et al. Prognostic utility of Hyams histological grading and Kadish‒Morita staging systems for esthesioneuroblastoma outcomes. Head Neck Pathol. 2015;9(01):51‐59.